People Act like US Government is the only buyer of Vaccines!!
Everyone getting their jollies in a wad over these Nova, J&J, Moderna deals is a bit short-sighted. These deals are all contingent on the vaccines actually working. Just because you are first to trial doesn't mean the vaccine with work. Meanwhile, INO already has positive data on another Coronavirus vaccine candidate (INO-4700):
Dr. J. Joseph Kim, INOVIO's President & CEO, said, "The INO-4700 Phase 1/2a clinical trial data demonstrates that our MERS DNA vaccine is able to generate robust immune responses using INOVIO's intradermal CELLECTRA delivery system. This exciting data provides a great foundation for the ongoing COVID-19 vaccine advancement as it demonstrates the power of INOVIO's delivery system and the strength of our coronavirus experience. As we have designed our COVID-19 vaccine INO-4800 using the same strategy as INO-4700, including the selection of full length Spike protein as the target and the use of intradermal CELLECTRA device, we are hopeful that the ongoing Phase 1 clinical trial with INO-4800 would generate similar clinical immune responses and safety data as we have just reported for INO-4700."
Overall, for those receiving 0.6 mg of INO-4700, 88% demonstrated seroconversion after a 2 dose regimen at 0 and 8 weeks, while for those receiving a 3 dose regimen given at 0, 4 and 12 weeks, 84% seroverted after 2 doses and 100% after 3 doses, as measured by a binding antibody assay against the full-length S protein (ELISA). Additionally, 92% of the vaccine recipients in both groups displayed the ability to neutralize the virus using a neutralization assay (EMC2012-Vero neutralization). Robust T cell responses were observed in 60% of vaccine recipients after the 2 dose regimen and 84% of those in the 3 dose group (ELISpot assay). Interestingly, a single dose of 0.6 mg of INO-4700 intradermal vaccination resulted in 74% binding antibody response rate and 48% neutralization antibody response rate.
No reason to believe INO-4800 is not seeing similar success.
It was recently reported that an over 50% success rate for a vaccine would be a go for the FDA.
INO doesn't have to be Fauci's love child like Moderna to make mad money. Why?
INO is working with partners in both South Korea and China.
There are over 300 million people in the U.S. Meanwhile, in China and South Korea alone, there are around 2 billion people. And their money is good here!
Just transferred another 100k to my Schwab account. If INO dips to 18.5, I'm increasing my holdings to 50k shares.
